Clinical Trials Browser

Neoplasms, Plasma Cell × Standard of Care × 1 year × Clear all

NCT06504524 2025-06-27

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

633 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell